PTPRJ pep-19.5
General Information
DRACP ID DRACP02044
Peptide Name PTPRJ pep-19.5
Sequence CHHNATHAC
Sequence Length 9
UniProt ID Not available
PubChem CID Not available
Origin Synthetic (Derived from PTPRJ pep-19)
Type Synthetic peptide
Classification
Active ACP Cancer targeted peptides PTPRJ agonist
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
HeLa | Human papillomavirus-related endocervical adenocarcinoma | Carcinoma | 2 ± 1.5% Inhibition=160 μM | Trypan blue assay | 48 h | 1 |
HeLa | Human papillomavirus-related endocervical adenocarcinoma | Carcinoma | 19 ± 4.2% Inhibition=160 μM | Trypan blue assay | 72 h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target PTPRJ
Affinity Not available
Mechanism PTPRJ is a receptor-type protein tyrosine phosphatase whose expression is strongly reduced in the majority of investigated cancer cell lines and tumor specimens.It showed tumor suppressor activity in several models.
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Cyclic
Disulfide/Other Bond Cys1<--->Cys9
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C38H56N16O12S2
Absent amino acids DEFGIKLMPQRSVWY
Common amino acids H
Mass 113598
Pl 7.52
Basic residues 3
Acidic residues 0
Hydrophobic residues 2
Net charge 3
Boman Index -1701
Hydrophobicity -57.78
Aliphatic Index 22.22
Half Life
Mammalian: 1.2 hour
Yeast: >20 hour
E.coli: >10 hour
Extinction Coefficient cystines 125
Absorbance 280nm 15.63
Polar residues 4
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 23627474
Title Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation
Year 2013
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
External Code